MedPath

Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy

Phase 3
Completed
Conditions
Tobacco Dependence
Interventions
Registration Number
NCT02355665
Lead Sponsor
McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.
Brief Summary

The purpose of this study is to assess the efficacy and safety of a novel nicotine product for continuous abstinence from smoking. Efficacy of product will be evaluated by assessments of self-reported abstinence, verified by exhaled carbon monoxide (CO) levels.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1198
Inclusion Criteria

Subjects must be males or females 18-85 years of age who currently smoke cigarettes daily and are willing to stop smoking

Exclusion Criteria

History of cardiovascular disease, stomach ulcer or diabetes unless physician's written approval is obtained.

Use of other forms of tobacco/nicotine containing products other than cigarettes within 30 days before baseline visit.

Use of nicotine replacement therapies or other smoking cessation medicines/non-drug therapies within 30 days before the baseline visit.

Pregnancy or intending to become pregnant.

Hypersensitivity to the product, history of alcohol or substance abuse.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NicotineNicotine SprayNicotine Spray
PlaceboPlaceboPlacebo to match Nicotine spray
Primary Outcome Measures
NameTimeMethod
Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 6Week 2 to Week 6

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in Systolic Blood Pressure at Week 8Baseline to Week 8

Change from baseline in systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 20Baseline to Week 20

Change from baseline in systolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 1Week 1

Diastolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 2Week 2

Diastolic blood pressure (mm Hg)

Pulse at Week 20Week 20

Pulse (beats per minute)

Change From Baseline in Diastolic Blood Pressure at Week 12Baseline to Week 12

Change from baseline in diastolic blood pressure (mm Hg)

Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Total Daily Number of Self-Reported Spray Doses at Week 12Week 12

Total Daily Number of Self-Reported Spray Doses

Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Maximum Hourly Number of Self-Reported Spray Doses at Week 1Week 1

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 5Week 5

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 11Week 11

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 15Week 15

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 16Week 16

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 21Week 21

Maximum Hourly Number of Self-Reported Spray Doses

Number of Cigarettes Smoked Since Last Visit at Week 2Week 2

Number of Cigarettes Smoked Since Last Visit

Maximum Total Daily Number of Self-Reported Spray Doses at Week 11Week 11

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 16Week 16

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 17Week 17

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 19Week 19

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 20Week 20

Maximum Total Daily Number of Self-Reported Spray Doses

Number of Cigarettes Smoked Per Day at Week 12Week 12

Number of Cigarettes Smoked Per Day

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 12Week 2 to Week 12

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 26Week 2 to Week 26

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 4Week 2 to Week 4

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 16Week 2 to Week 16

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Total Daily Number of Self-Reported Spray Doses at Week 13Week 13

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 15Week 15

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 20Week 20

Total Daily Number of Self-Reported Spray Doses

Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Desire/Urge to Smoke on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced the desire/urge to smoke on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 20Week 2 to Week 20

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage Distribution of the Rating of Irritability/Frustration/Anger on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced irritability/frustration/anger on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Anxiety on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced anxiety on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Maximum Total Daily Number of Self-Reported Spray Doses at Week 5Week 5

Maximum Total Daily Number of Self-Reported Spray Doses

Percentage of Participants With Continuous Smoking Abstinence From Week 2 to Week 8Week 2 to Week 8

Percentage of participants with carbon monoxide (CO)-verified self-report of continuous abstinence from smoking

Percentage Distribution of the Rating of Insomnia on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced insomnia on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Total Daily Number of Self-Reported Spray Doses at Week 1Week 1

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 5Week 5

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 6Week 6

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 9Week 9

Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 6Week 6

Maximum Total Daily Number of Self-Reported Spray Doses

Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Restlessness on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced restlessness on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Maximum Total Daily Number of Self-Reported Spray Doses at Week 7Week 7

Maximum Total Daily Number of Self-Reported Spray Doses

Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 1Week 1

Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Difficulty Concentrating on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced difficulty concentrating on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 4Week 4

Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Aggregated Withdrawal Score at Week 4Week 4

Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.

Maximum Total Daily Number of Self-Reported Spray Doses at Week 10Week 10

Maximum Total Daily Number of Self-Reported Spray Doses

Percentage Distribution of the Rating of Dysphoric or Depressed Mood on a Categorical Scale at Week 2Week 2

Participants were asked if during the last 24 hours they experienced dysphoric or depressed mood on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Aggregated Withdrawal Score at Week 1Week 1

Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.

Total Daily Number of Self-Reported Spray Doses at Week 7Week 7

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 17Week 17

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 18Week 18

Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 3Week 3

Maximum Total Daily Number of Self-Reported Spray Doses

Aggregated Withdrawal Score at Week 2Week 2

Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.

Percentage Distribution of the Rating of Increased Appetite on a Categorical Scale at Week 6Week 6

Participants were asked if during the last 24 hours they experienced increased appetite on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so).

Total Daily Number of Self-Reported Spray Doses at Week 3Week 3

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 4Week 4

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 8Week 8

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 10Week 10

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 16Week 16

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 19Week 19

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 21Week 21

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 22Week 22

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 24Week 24

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 25Week 25

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 26Week 26

Total Daily Number of Self-Reported Spray Doses

Aggregated Withdrawal Score at Week 6Week 6

Participants were asked if during the last 24 hours they experienced each of 7 withdrawal symptoms on a 5-grade categorical scale of 0 - 4 (where 0=not at all and 4=extremely so). The aggregated withdrawal symptom score was the sum of the scores of the 7 withdrawal symptoms (irritability-frustration-anger, restlessness, difficulty concentrating, anxiety, dysphoric or depressed mood, insomnia, and increased appetite). The total scores are reported with a minimum possible score of 0 and a maximum possible score of 28.

Total Daily Number of Self-Reported Spray Doses at Week 2Week 2

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 11Week 11

Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 14Week 14

Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 15Week 15

Maximum Total Daily Number of Self-Reported Spray Doses

Total Daily Number of Self-Reported Spray Doses at Week 23Week 23

Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 1Week 1

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 2Week 2

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 9Week 9

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 12Week 12

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 14Week 14

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 23Week 23

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 3Week 3

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 6Week 6

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 7Week 7

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 12Week 12

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 13Week 13

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 8Week 8

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 13Week 13

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 18Week 18

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 14Week 14

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 23Week 23

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 24Week 24

Maximum Hourly Number of Self-Reported Spray Doses

Number of Cigarettes Smoked Per Day at Week 16Week 16

Number of Cigarettes Smoked Per Day

Number of Cigarettes Smoked Per Day at Week 26Week 26

Number of Cigarettes Smoked Per Day

Percentage Distribution of the Participant Score for Overall Product Rating at Week 1Week 1

Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).

Maximum Total Daily Number of Self-Reported Spray Doses at Week 4Week 4

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 21Week 21

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 24Week 24

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 26Week 26

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 4Week 4

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 8Week 8

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 9Week 9

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 10Week 10

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 17Week 17

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 19Week 19

Maximum Hourly Number of Self-Reported Spray Doses

Number of Cigarettes Smoked Since Last Visit at Week 1Week 1

Number of Cigarettes Smoked Since Last Visit

Number of Cigarettes Smoked Per Day at Week 4Week 4

Number of Cigarettes Smoked Per Day

Maximum Hourly Number of Self-Reported Spray Doses at Week 18Week 18

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 20Week 20

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 22Week 22

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Total Daily Number of Self-Reported Spray Doses at Week 25Week 25

Maximum Total Daily Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 2Week 2

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 26Week 26

Maximum Hourly Number of Self-Reported Spray Doses

Number of Cigarettes Smoked Per Day at Week 6Week 6

Number of Cigarettes Smoked Per Day

Number of Cigarettes Smoked Per Day at Week 8Week 8

Number of Cigarettes Smoked Per Day

Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 6Week 6

Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).

Systolic Blood Pressure at Week 6Week 6

Systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 8Week 8

Systolic blood pressure (mm Hg)

Maximum Hourly Number of Self-Reported Spray Doses at Week 22Week 22

Maximum Hourly Number of Self-Reported Spray Doses

Maximum Hourly Number of Self-Reported Spray Doses at Week 25Week 25

Maximum Hourly Number of Self-Reported Spray Doses

Percentage Distribution of the Participant Score for Overall Product Rating at Week 12Week 12

Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).

Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 12Week 12

Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).

Percentage Distribution of the Participant Score for Change of Opinion at Week 1 Concerning Product Compared to When First Used ProductWeek 1

Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).

Number of Cigarettes Smoked Per Day at Week 20Week 20

Number of Cigarettes Smoked Per Day

Percentage Distribution of the Participant Score for Overall Product Rating at Week 6Week 6

Participants were asked to rate the investigational product on a 10-point scale of 1 - 10 (where 1=very poor and 10=excellent).

Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 1Week 1

Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).

Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 12Week 12

Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).

Systolic Blood Pressure at Week 1Week 1

Systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 20Week 20

Systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 26Week 26

Systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 4Baseline to Week 4

Change from baseline in systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 2Week 2

Systolic blood pressure (mm Hg)

Percentage Distribution of the Participant Score for Product Effectiveness in Dealing With Desire/Urge to Smoke at Week 6Week 6

Participants were asked to rate the product in its effectiveness for dealing with desire/urge to smoke on a 5-point scale of 1 - 5 (where 1=not all effective and 5=extremely effective).

Percentage Distribution of the Participant Score for Speed of Action of the Product at Week 1Week 1

Participants were asked to rate the speed of action of the product on a 9-point scale of 1 - 9 (where 1=extremely slow and 9=extremely fast).

Percentage Distribution of the Participant Score for Product Convenience at Week 6Week 6

Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).

Change From Baseline in Systolic Blood Pressure at Week 1Baseline to Week 1

Change from baseline in systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 6Baseline to Week 6

Change from baseline in systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 12Baseline to Week 12

Change from baseline in systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 26Baseline to Week 26

Change from baseline in systolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 6Week 6

Diastolic blood pressure (mm Hg)

Change From Baseline in Pulse at Week 2Baseline to Week 2

Change from baseline in pulse (beats per minute)

Percentage Distribution of the Participant Score for Change of Opinion at Week 6 Concerning Product Compared to When First Used ProductWeek 6

Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).

Percentage of Participants With New or Worsened Conditions in Tongue at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Percentage Distribution of the Participant Score for Change of Opinion at Week 12 Concerning Product Compared to When First Used ProductWeek 12

Participants were asked to rate their change of opinion concerning product compared to when first used product on a 5-point scale of 1 - 5 (where 1=I like it much less now and 5=I like it much more now).

Percentage Distribution of the Participant Score for Product Convenience at Week 1Week 1

Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).

Percentage Distribution of the Participant Score for Product Convenience at Week 12Week 12

Participants were asked to rate the product convenience on a 5-point scale of 1 - 5 (where 1=not at all convenient and 5=extremely convenient).

Systolic Blood Pressure at Week 4Week 4

Systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 12Week 12

Systolic blood pressure (mm Hg)

Systolic Blood Pressure at Week 16Week 16

Systolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 16Week 16

Diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 6Baseline to Week 6

Change from baseline in diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 26Baseline to Week 26

Change from baseline in diastolic blood pressure (mm Hg)

Pulse at Week 2Week 2

Pulse (beats per minute)

Pulse at Week 4Week 4

Pulse (beats per minute)

Pulse at Week 16Week 16

Pulse (beats per minute)

Change From Baseline in Pulse at Week 1Baseline to Week 1

Change from baseline in pulse (beats per minute)

Change From Baseline in Pulse at Week 8Baseline to Week 8

Change from baseline in pulse (beats per minute)

Change From Baseline in Systolic Blood Pressure at Week 2Baseline to Week 2

Change from baseline in systolic blood pressure (mm Hg)

Change From Baseline in Systolic Blood Pressure at Week 16Baseline to Week 16

Change from baseline in systolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 12Week 12

Diastolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 20Week 20

Diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 4Baseline to Week 4

Change from baseline in diastolic blood pressure (mm Hg)

Pulse at Week 8Week 8

Pulse (beats per minute)

Pulse at Week 12Week 12

Pulse (beats per minute)

Change From Baseline in Pulse at Week 12Baseline to Week 12

Change from baseline in pulse (beats per minute)

Change From Baseline in Pulse at Week 26Baseline to Week 26

Change from baseline in pulse (beats per minute)

Percentage of Participants With New or Worsened Conditions in Buccal Mucosa at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Percentage of Participants With New or Worsened Conditions in Sublingual Mucosa at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Change From Baseline in Diastolic Blood Pressure at Week 20Baseline to Week 20

Change from baseline in diastolic blood pressure (mm Hg)

Pulse at Week 1Week 1

Pulse (beats per minute)

Pulse at Week 6Week 6

Pulse (beats per minute)

Diastolic Blood Pressure at Week 4Week 4

Diastolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 8Week 8

Diastolic blood pressure (mm Hg)

Diastolic Blood Pressure at Week 26Week 26

Diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 1Baseline to Week 1

Change from baseline in diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 2Baseline to Week 2

Change from baseline in diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 8Baseline to Week 8

Change from baseline in diastolic blood pressure (mm Hg)

Change From Baseline in Diastolic Blood Pressure at Week 16Baseline to Week 16

Change from baseline in diastolic blood pressure (mm Hg)

Pulse at Week 26Week 26

Pulse (beats per minute)

Change From Baseline in Pulse at Week 4Baseline to Week 4

Change from baseline in pulse (beats per minute)

Change From Baseline in Pulse at Week 6Baseline to Week 6

Change from baseline in pulse (beats per minute)

Change From Baseline in Pulse at Week 16Baseline to Week 16

Change from baseline in pulse (beats per minute)

Change From Baseline in Pulse at Week 20Baseline to Week 20

Change from baseline in pulse (beats per minute)

Percentage of Participants With New or Worsened Conditions in Mucobuccal Fold at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Change From Baseline in Body Weight at Week 12Baseline to Week 12

Change from baseline in body weight

Change From Baseline in Body Weight at Week 6 in Participants Verified Continuously Abstinent From Smoking From the Week 2 VisitBaseline to Week 6

Change from baseline in body weight

Change From Baseline in Body Weight at Week 12 in Participants Verified Continuously Abstinent From Smoking From the Week 2 VisitBaseline to Week 12

Change from baseline in body weight

Change From Baseline in Body Weight at Week 26 in Participants Verified Continuously Abstinent From Smoking From the Week 2 VisitBaseline to Week 26

Change from baseline in body weight

Percentage of Participants With New or Worsened Conditions in Lips/Labial Mucosa at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Percentage of Participants With New or Worsened Conditions in Gingiva at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Percentage of Participants With New or Worsened Conditions in Hard/Soft Palate at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Percentage of Participants With New or Worsened Conditions in Visual Mouth Inspection Overall at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Change From Baseline in Body Weight at Week 6Baseline to Week 6

Change from baseline in body weight

Change From Baseline in Body Weight at Week 26Baseline to Week 26

Change from baseline in body weight

Percentage of Participants With New or Worsened Conditions in Uvula/Oropharynx at Week 6 or When Withdrawn From StudyWeek 6 or when withdrawn from study

Visual mouth inspection (VMI) performed at the site or local dental office by a licensed dentist or an examiner such as a dental hygienist with documented training in oral clinical exams. Extraoral and intraoral tissues were examined. Abnormalities were recorded; it was determined if abnormalities were new or had worsened since baseline VMI findings.

Trial Locations

Locations (6)

Los Angeles Clinical Trials

🇺🇸

Burbank, California, United States

Radiant Research, Inc

🇺🇸

Salt Lake City, Utah, United States

University of Maryland

🇺🇸

College Park, Maryland, United States

Radiant Research, Inc.

🇺🇸

Akron, Ohio, United States

Mayo Clinic

🇺🇸

Scottsdale, Arizona, United States

Radiant Research

🇺🇸

Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath